New cancer-fighting immunotherapy enters clinical trials

Researchers from the MDC and Charité have developed a new gene therapy based around a special T-cell receptor that helps the immune system effectively recognize and fight cancer cells. The safety of the novel therapy is now being tested on patients…

6 Min
More

GILUPI and SCIENION announce Collaboration for the Development of Single-Cell CTC Analysis

GILUPI GmbH and SCIENION AG announced on March 18that the companies intend to intensify their collaboration in the field of single circulating tumor cell (CTC) analysis. CTCs are rare cells that can be found in the peripheral blood of cancer…

3 Min
More

First-in-human clinical study results

 

Cardio-microcurrent device for chronic heart failure: first-in-human clinical study

Most devices for treating ambulatory Class II and III heart failure are linked to electrical pulses. However, a steady electric potential gradient is also…

1 Min
More

Lab to market a program for researchers in Advanced Materials

 

Lab to market is a program for researchers in

Advanced Materials. If you are considering commercialising your technology, this program is for you.

We aim to turn scientists into science entrepreneurs.

 

 

Are you doing research in Advanced…

1 Min
More

The start up accelerator for advanced materials

 

The Advanced Materials Competition (AdMaCom) is a fast-paced 2 week Accelerator Program for Startups in Advanced Materials. 

AdMaCom focuses on: IP Strategy, Investment & funding opportunities, Technical & Business Mentoring, Pitch training and…

1 Min
More

Open innovation challenge for Sustainable materials solutions

Rubbers & plastics for the automotive industry

1 Min
More

SCIENION continues to grow and will build new headquarters in Berlin Adlershof

SCIENION AG, located in the Technology Park Adlershof since its foundation in 2001, today announced that the expanding company will build larger new headquarters at Wagner-Régeny Street in the same district of Berlin.

2 Min
More

GeneQuine Biotherapeutics Secures More Than €9 Million in Series A Financing and Non-Dilutive Funding to Advance Gene Therapy Pipeline for Musculoskeletal Diseases

• Proceeds will facilitate development of GeneQuine’s gene therapy pipeline for musculoskeletal disorders and vector platform

• Lead gene therapy candidate GQ-303, a potentially disease-modifying treatment for osteoarthritis, will be advanced to…

7 Min
More

Glycotope announces licensing agreement with ONK Therapeutics for humanized GlycoBody targeting TA-MUC1

GlycoBody to be integrated into ONK pre-clinical program ONKT103, for solid tumors.

3 Min
More

Alrise announces acquisition of its ImSus® drug delivery technology by Ferring International Center S.A.

 

The drug delivery specialist Alrise Biosystems GmbH has entered into an Asset Purchase and Exclusive License Agreement with Ferring International Center S.A. for the development and commercialisation of products manufactured with Alrise’s ImSus®…

1 Min
More
Show more items